Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
M-9140 by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
M-9140 is under clinical development by Merck and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
(Pembrolizumab + quavonlimab) by Merck for Melanoma: Likelihood of Approval
(Pembrolizumab + quavonlimab) is under clinical development by Merck and currently in Phase II for Melanoma. According to GlobalData, Phase...
Avelumab by Merck for Small-Cell Lung Cancer: Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Pembrolizumab by Merck for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer...
Pembrolizumab by Merck for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Pembrolizumab by Merck for Gliosarcoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs...
Pembrolizumab by Merck for Uterine Cancer: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...
Pembrolizumab by Merck for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...
MK-1084 by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
MK-1084 is under clinical development by Merck and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Letermovir by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Letermovir is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Pembrolizumab by Merck for Kaposi Sarcoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I...
Pembrolizumab by Merck for Bladder Cancer: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...
Pembrolizumab by Merck for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Berzosertib by Merck for Solid Tumor: Likelihood of Approval
Berzosertib is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
PRA-052 by Merck for Ulcerative Colitis: Likelihood of Approval
PRA-052 is under clinical development by Merck and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I...
MK-8527 by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
MK-8527 is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Risk adjusted net present value: What is the current valuation of Merck's Nemtabrutinib?
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL). According...
Risk adjusted net present value: What is the current valuation of Merck's Favezelimab?
Favezelimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...
Risk adjusted net present value: What is the current valuation of Merck's Quavonlimab?
Quavonlimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's Vibostolimab?
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...